CA3183555A1 - Compositions and methods for treating hemorrhagic shock - Google Patents

Compositions and methods for treating hemorrhagic shock

Info

Publication number
CA3183555A1
CA3183555A1 CA3183555A CA3183555A CA3183555A1 CA 3183555 A1 CA3183555 A1 CA 3183555A1 CA 3183555 A CA3183555 A CA 3183555A CA 3183555 A CA3183555 A CA 3183555A CA 3183555 A1 CA3183555 A1 CA 3183555A1
Authority
CA
Canada
Prior art keywords
hboc
weight
blood plasma
ions
oxygenation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183555A
Other languages
English (en)
French (fr)
Inventor
William Richard Light Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virtech Bio Inc
Original Assignee
Virtech Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virtech Bio Inc filed Critical Virtech Bio Inc
Publication of CA3183555A1 publication Critical patent/CA3183555A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3183555A 2020-06-23 2021-06-23 Compositions and methods for treating hemorrhagic shock Pending CA3183555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042668P 2020-06-23 2020-06-23
US63/042,668 2020-06-23
PCT/US2021/038606 WO2021262803A1 (en) 2020-06-23 2021-06-23 Compositions and methods for treating hemorrhagic shock

Publications (1)

Publication Number Publication Date
CA3183555A1 true CA3183555A1 (en) 2021-12-30

Family

ID=79281812

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183555A Pending CA3183555A1 (en) 2020-06-23 2021-06-23 Compositions and methods for treating hemorrhagic shock

Country Status (7)

Country Link
US (1) US20230241184A1 (enExample)
EP (2) EP4782058A2 (enExample)
JP (1) JP2023531508A (enExample)
AU (1) AU2021297879A1 (enExample)
CA (1) CA3183555A1 (enExample)
ES (1) ES3073540T3 (enExample)
WO (1) WO2021262803A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025091017A1 (en) * 2023-10-27 2025-05-01 Ohio State Innovation Foundation Synthetic whole blood substitutes
US12419850B1 (en) 2024-03-21 2025-09-23 GanD, Inc. Bioactive fluid compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5407579A (en) 1993-07-02 1995-04-18 National Science Council Hemoglobin purification
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
JP3664328B2 (ja) 1996-01-19 2005-06-22 富士写真フイルム株式会社 血漿または血清試料の調製方法
CA2254223A1 (en) 1998-11-16 2000-05-16 Biophys, Inc. Device and method for analyzing a biologic sample
US6518010B2 (en) * 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
US7144989B2 (en) 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7135554B1 (en) * 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
TWI332813B (en) 2007-05-11 2010-11-01 Unimicron Technology Corp Process of structure with embedded circuit
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
BRPI1006722A2 (pt) 2009-04-09 2017-10-10 Entegrion Inc "método de preparação de hemoderivados desidratado, hemoderivados desidratados, bandagem ou auxílio cirúrgico, método para a preparação de plaquetas sanguíneas fixas desidratadas, plaquetas sanguíneas fixas desidratadas, método para o tratamento de um paciente que sofre de um distúrbio sanguíneo e plaquetas de sangue fixas secas por atomização tendo geometria com cavidades esféricas"
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US20120028899A1 (en) 2010-07-30 2012-02-02 Andre Francis Palmer Composition and process for synthesizing tense and relaxed state polymerized hemoglobin
US8609815B2 (en) 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
US10426820B2 (en) 2011-04-13 2019-10-01 Case Western Reserve University Synthetic platelets
WO2014033208A1 (en) 2012-08-30 2014-03-06 Qiagen Gmbh A method for obtaining blood plasma from a whole blood sample
US9304142B1 (en) 2013-03-12 2016-04-05 A. Steve Gurganian Energy harvesting zero-speed sensor device, method and system
JP6461005B2 (ja) * 2013-11-21 2019-01-30 協和メデックス株式会社 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法
AU2015301014B2 (en) * 2014-08-08 2021-05-06 Poseida Therapeutics, Inc. Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
EP3849570A4 (en) * 2018-09-11 2023-07-12 Cellphire Inc. Blood plasma-containing compositions
CA3143968A1 (en) * 2019-07-02 2021-02-25 Hbo2 Therapeutics, Llc Hemoglobin substitute mixtures including reconstituted plasma and platelets and their manufacture and use
US20210023140A1 (en) 2019-07-26 2021-01-28 Prp Scientific, Inc. Platelet formulations and medical uses thereof

Also Published As

Publication number Publication date
ES3073540T3 (en) 2026-07-13
EP4167961B1 (en) 2026-04-29
EP4167961A4 (en) 2024-03-13
EP4167961C0 (en) 2026-04-29
US20230241184A1 (en) 2023-08-03
AU2021297879A1 (en) 2023-02-09
EP4782058A2 (en) 2026-07-29
WO2021262803A1 (en) 2021-12-30
EP4167961A1 (en) 2023-04-26
JP2023531508A (ja) 2023-07-24

Similar Documents

Publication Publication Date Title
Spiess Transfusion of blood products affects outcome in cardiac surgery
EP0277289B2 (en) Extra pure semi-synthetic blood substitute
US5084558A (en) Extra pure semi-synthetic blood substitute
US8349367B2 (en) Freeze-dried plasma formats for the trauma care field
US5213814A (en) Lyophilized and reconstituted blood platelet compositions
ES3042959T3 (en) Methods for the storage of whole blood, and compositions thereof
EP4167961B1 (en) Compositions and methods for treating hemorrhagic shock
US5153004A (en) Freezing and thawing of erythrocytes
EA030017B1 (ru) Композиция для наружной обработки ран, способ ее получения, применение переносчика кислорода для наружной обработки ран и способ очистки переносчика кислорода
MX2008014648A (es) Metodos para tratar la anemia aguda por perdida de sangre con un sustituto de la sangre con hemoglobina reticulada.
AU2019337591A1 (en) Blood plasma-containing compositions
WO2022239870A1 (ja) 血液由来成長因子含有組成物及びその調製方法
Evarts Low molecular weight dextran
Lauby et al. A Scoping Review of Promising Alternative Blood Products for Prolonged Field Care.
WO2024122618A1 (ja) 成長因子含有組成物の調製方法
Awasthi Pharmaceutical aspects of hemoglobin-based oxygen carriers
Strautz et al. Compatibility of ADSOL-stored red cells with intravenous solutions
Harmening et al. Red Blood Cell, and Platelet Preservation: Historical Perspective, Review of Metabolism and Current Trends
Callan et al. Platelet products
US20240049700A1 (en) Lipid layer preservation
Becker et al. Use of PGE (1) in preparation and storage of platelet concentrates
US20220280606A1 (en) Method of preparing a de-fibrinated platelet lysate, and uses of said method
Buzzard et al. Blood Component Alternatives During Acute Hemorrhage
RU2308279C1 (ru) Способ подготовки сырья для производства лекарственных средств из крови
WO2025254209A1 (ja) クエン酸を含む血液由来成長因子含有組成物及びその調製方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250324

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250623

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250627

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250827

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250827

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250827

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250827

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260602

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260626